|
Anagrelide (Agrylin/Xagrid, Shire and Thromboreductin, (AOP Orphan Pharmaceuticals )) is a drug used for the treatment of essential thrombocytosis (ET; essential thrombocythemia), or overproduction of blood platelets. It also has been used in the treatment of chronic myeloid leukemia. == Medical uses == Anagrelide is used to treat essential thrombocytosis, especially when the current treatment of the patient is insufficient. Essential thrombocytosis patients who are suitable for anagrelide often meet one or more of the following factors: * age over 60 years * platelet count over 1000×109/L * a history of thrombosis According to a 2005 Medical Research Council randomized trial, the combination of hydroxyurea with aspirin is superior to the combination of anagrelide and aspirin for the initial management of ET. The hydroxyurea arm had a lower likelihood of myelofibrosis, arterial thrombosis, and bleeding, but it had a slightly higher rate of venous thrombosis.〔 Anagrelide can be useful in times when hydroxyurea proves ineffective. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Anagrelide」の詳細全文を読む スポンサード リンク
|